source
- Tolerance Bio signs up to $560M deal for anti-IL-33 drug from TanabeTolerance Bio has licensed the rights to an anti‑IL‑33 monoclonal antibody from Mitsubishi Tanabe Pharma for use outside Japan. The antibody, previously known as MT‑2990 and to be renamed TLB‑33, w…
- Precision Neuroscience raises $250M in Series D to expand brain-computer interface programPrecision Neurosciences announced a $250 million Series D financing round that was oversubscribed. The capital injection follows previous rounds that have brought the company’s total funding to $43…